Pluvicto (lutetium-177 vipivotide tetraxetan) is a radioligand therapy that targets the PSMA protein on prostate cancer cells ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

(ST. JOSEPH, Mo) Mosaic Life Care is advancing its cancer treatment for patients with metastatic prostate cancer. PLUVICTO is ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch of novel therapies such as BXCL701, Peluntamig, ...

Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply to new ...

New report finds colorectal cancer rising among U.S. adults under 55 Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week.

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis to Make Pluvicto Radioligand Therapy at Indianapolis Plant Production boost to meet growing demand from cancer patients in North America By Mauro Orru Jan. 5, 2024 3:33 pm ET ...

Shortage of Last-Ditch Drug for Advanced Prostate Cancer Worries Doctors Novartis seeks to ramp up Pluvicto production to ease supply issues By Jennifer Calfas and Melanie Evans March 16, 2023 5: ...